Tagged with cancer

Hong Kong Haematological oncologist Dr Raymond Liang, gives his take on the adoption and challenges of CAR-T therapy in Hong Kong, the necessity of collaboration with mainland China for patient referrals and clinical trials, and the evolution of both Hong Kong’s hospital and regulatory infrastructure, which point to a brighter future for…

India Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened up its clinical research regulations and saw a significant drop in trial numbers. However, with a revised regulatory landscape, a…

France As president of the French League Against Cancer, Dr Daniel Nizri highlights the organization’s 106-year legacy of fighting cancer through research funding, health promotion, patient support, and advocacy. He discusses the National Cancer Plan 2030’s ambitious goals amidst the realities of healthcare system inequalities, the impact of the COVID-19 pandemic,…

India Director of the oldest and largest cancer centre in India, the Tata Memorial Hospital, C S Pramesh also heads up the National Cancer Grid (NCG), a nationwide network of over 300 cancer centres and research institutions. He outlines the pioneering research-based work of the Tata Memorial Hospital and explains the…

India Over the course of his 40-year career, oncologist Dr Ramakant Deshpande has taken an active role in the evolution of cancer care in India and in 2017 he became the executive chairman of the Asian Cancer Institute, a cancer care centre aimed at delivering quality care while addressing affordability. He…

UAE Friends of Cancer Patients (FoCP) is a non-profit organisation, founded in 1999, that supports cancer patients, their families, donors, and the overall community in the UAE. Director Aisha Abdulla Al Mulla highlights some of the FoCP’s key initiatives around early cancer detection and screening, where the UAE’s patient advocacy landscape…

Belgium PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last conversation in 2020, and his hopes for establishing new alliances with manufacturers and Big Pharma players moving forward.   Our…

China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…

Taiwan The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular degeneration drug development, and Ever Supreme Bio Technology’s cell therapy progress.   New Gongwin-KY lung cancer drug cleared for marketing…

Global Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as a revolutionary, perhaps even decisive, new pillar in the war on cancer. Five years later, however, many are still left…

Global In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand along the life science continuum, providing positive healthcare…

Japan Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology operations. Horii also touches on the significant burden of cancer in Japan, how Takeda’s solutions help meet some of the country’s most significant unmet cancer needs, as well…